SCHEMBL16946892

SCHEMBL16946892

CCOC(=O)c1cnn2ccc(N(CC)Cc3cc(F)ccc3O)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 3/20 0.45
▸ KDM4E B2RXH2 6/20 0.45
▸ HSD17B10 Q99714 5/20 0.45
▸ HPGD P15428 5/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ NTRK1 P04629 4/20 0.42
▸ TSHR P16473 2/20 0.40
▸ CSNK1D P48730 2/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ LMNA P02545 1/20 0.36
▸ NTRK3 Q16288 1/20 0.36
▸ NTRK2 Q16620 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29511265 0.90 NTRK1 (0.49) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL16935988 0.90 NTRK1 (0.49) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL16946894 0.90 TGFBR1 (0.42) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL30092497 0.90 TGFBR1 (0.42) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL16946699 0.83 KDM4E (0.46) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL20681128 0.83 TGFBR1 (0.47) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL16935987 0.82 NTRK1 (0.48) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL16946746 0.82 NTRK1 (0.48) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL30092502 0.82 NTRK1 (0.48) TGFBR1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL16946782 0.82 TGFBR1 (0.46) TGFBR1KDM4EHSD17B10HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404281-B2 Diaryl macrocycles as modulators of protein kinases Turning Point Therapeutics, Inc. (US) 2025-09-02 — — US disclosed
US-20240140964-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2024-05-02 — — US disclosed
EP-4338739-A2 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2024-03-20 — — EP disclosed
EP-3636649-B1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TURNING POINT THERAPEUTICS INC (US) 2024-02-14 — — EP disclosed
EP-3572416-B1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TURNING POINT THERAPEUTICS INC (US) 2022-09-21 — — EP disclosed
US-20220112213-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. 2022-04-14 — — US disclosed
US-20200216465-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TURNING POINT THERAPEUTICS INC (US) 2020-07-09 — — US disclosed
US-20200216465-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TURNING POINT THERAPEUTICS INC (US) 2020-07-09 — — US disclosed
EP-3636650-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
EP-3636649-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
US-10246466-B2 Diaryl macrocycles as modulators of protein kinases TP THERAPEUTICS, INC. (US) 2019-04-02 — — US disclosed
US-10246466-B2 Diaryl macrocycles as modulators of protein kinases TP THERAPEUTICS, INC. (US) 2019-04-02 — — US disclosed
US-20170334929-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. 2017-11-23 — — US disclosed
US-20170334929-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. 2017-11-23 — — US disclosed
US-20170334929-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. 2017-11-23 — — US disclosed
US-9714258-B2 Diaryl macrocycles as modulators of protein kinases TP THERAPEUTICS, INC. (US) 2017-07-25 — — US disclosed
US-9714258-B2 Diaryl macrocycles as modulators of protein kinases TP THERAPEUTICS, INC. (US) 2017-07-25 — — US disclosed
US-20170002023-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS, INC. (US) 2017-01-05 — — US disclosed
US-20170002023-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS, INC. (US) 2017-01-05 — — US disclosed
WO-2015112806-A2 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS, INC. (US) 2015-07-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112213-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 TGFBR1 4041/4885KDM4E 1402/4885HSD17B10 4429/4885
US-12404281-B2 Diaryl macrocycles as modulators of protein kinases MAP3K20, LCK, MAP3K1 TGFBR1 4041/4885KDM4E 1402/4885HSD17B10 4429/4885
US-20240140964-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 TGFBR1 4041/4885KDM4E 1402/4885HSD17B10 4429/4885
US-20170334929-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 TGFBR1 4041/4885KDM4E 1402/4885HSD17B10 4429/4885
US-20200216465-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 TGFBR1 4041/4885KDM4E 1402/4885HSD17B10 4429/4885
US-10246466-B2 Diaryl macrocycles as modulators of protein kinases MAP3K20, LCK, MAP3K1 TGFBR1 4041/4885KDM4E 1402/4885HSD17B10 4429/4885
US-20170002023-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 TGFBR1 4041/4885KDM4E 1402/4885HSD17B10 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback